Expert Perspectives on a 77-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia

home / case-based-peer-perspectives / expert-perspectives-on-a-77-year-old-man-with-relapsed-chronic-lymphocytic-leukemia

Andrew Zelenetz, MD, reviews the diagnosis and treatment plan for a 77-year-old man with relapsed chronic lymphocytic leukemia (CLL) while highlighting several treatment options.

A 77-Year-Old Man with Chronic Lymphocytic Leukemia

EP. 1: A 77-Year-Old Man with Chronic Lymphocytic Leukemia

July 16th 2021

Andrew Zelenetz, MD, outlines the case of a 77-year-old man with chronic lymphocytic leukemia.

Watch

First-line Treatment Options in CLL

EP. 2: First-line Treatment Options in CLL

July 16th 2021

A key opinion leader highlights alternative treatment options to ibrutinib in the first-line setting for chronic lymphocytic leukemia.

Watch

Change in Therapy for CLL Due to Development of Atrial Fibrillation

EP. 3: Change in Therapy for CLL Due to Development of Atrial Fibrillation

July 16th 2021

Patient is switched for treatment of chronic lymphocytic leukemia from ibrutinib to idelalisib + rituximab due to development of atrial fibrillation.

Watch

Idelalisib + Rituximab in Previously Treated CLL Patients

EP. 4: Idelalisib + Rituximab in Previously Treated CLL Patients

July 16th 2021

Review of a phase III trial of idelalisib + rituximab in previously treated patients with chronic lymphocytic leukemia (CLL).

Watch

Management of Idelalisib Associated Diarrhea

EP. 5: Management of Idelalisib Associated Diarrhea

July 16th 2021

Andrew Zelenetz, MD, offers tips for management of idelalisib-associated diarrhea during treatment for chronic lymphocytic leukemia.

Watch

What is the Role of PI3K Inhibitors in the Treatment of CLL?

EP. 6: What is the Role of PI3K Inhibitors in the Treatment of CLL?

July 16th 2021

Andrew Zelenetz, MD, offers guidance on how PI3Ki (phosphoinositide 3-kinase inhibitors) fit into the treatment landscape of chronic lymphocytic leukemia.

Watch

Current and Future Challenges in the Treatment of CLL

EP. 7: Current and Future Challenges in the Treatment of CLL

July 16th 2021

Andrew Zelenetz, MD, reflects on the impact of moving agents to the frontline for treatment of chronic lymphocytic leukemia and how that impacts treatment decisions in relapsed/refractory chronic lymphocytic leukemia.

Watch